首頁 > 市場調查報告書 > 製藥

神經疾病

多發性硬化症市場規模、佔有率和成長分析（按藥物類別、診斷、給藥途徑、通路、最終用戶和地區分類）－產業預測（2026-2033年）

市場調查報告書

商品編碼

1898528

多發性硬化症市場規模、佔有率和成長分析（按藥物類別、診斷、給藥途徑、通路、最終用戶和地區分類）－產業預測（2026-2033年）

Multiple Sclerosis Market Size, Share, and Growth Analysis, By Drug Class (Immunomodulators, Immunosuppressants), By Diagnosis, By Route of Administration, By Distribution Channel, By End-Users, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 214 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球多發性硬化症 (MS) 市場規模將達到 266.4 億美元，到 2025 年將達到 272.5 億美元，到 2033 年將達到 326.9 億美元，預測期（2026-2033 年）的複合年成長率為 2.3%。

全球多發性硬化症 (MS) 的發展趨勢表明，由於其免疫介導的疾病特徵會嚴重損害中樞神經系統，因此對創新治療方法的需求日益成長。脫髓鞘和軸突喪失等關鍵病理狀況凸顯了有效治療方法的迫切性。去髓鞘化抗體，包括人源化單株抗體，處於治療研發的前沿，目前正在進行大量臨床試驗以發現新藥。 MS 盛行率的上升凸顯了診斷和治療的重要性，促使政府加強對治療的支持。為了推動市場發展，主要企業正致力於研發，同時，製藥公司與學術機構之間的合作也進一步促進了 MS 治療的進步，從而催生了一個快速發展的製藥行業，該行業專注於解決影響患者的各種症狀。

全球多發性硬化症市場促進因素

多發性硬化症盛行率的不斷上升是市場擴張的主要驅動力。這種神經系統疾病有多種類型，包括復發緩解型多發性硬化症 (RRMS)、首發漸進型(PPMS)、次發漸進型(SPMS) 和漸進復發型(PRMS)，每種類型都有較高的盛行率，並對市場動態產生影響。隨著這些不同類型多發性硬化症發病率的持續上升，對有效治療方法和先進治療方法的需求也在不斷成長，從而推動了該領域的創新和投資。人們對該疾病的認知不斷提高，並尋求更好的治療方案，這些因素共同促進了全球多發性硬化症市場的整體成長。

限制全球多發性硬化症市場的因素

全球多發性硬化症市場成長可能受到多種因素的限制。高昂的治療費用可能限制患者獲得治療的機會，進而抑制市場擴張。此外，在開發中國家，醫療基礎設施和合格醫護人員的匱乏進一步阻礙了治療的普及。近期發生的健康危機也導致就醫率下降，這可能會影響患者的治療順從性和治療的連續性。此外，大眾對多發性硬化症認知的普遍不足也為患者教育和診斷帶來了挑戰，最終阻礙因素了市場的整體成長潛力。

全球多發性硬化症市場趨勢

全球多發性硬化症市場正呈現出顯著的發展趨勢，主要得益於研發領域的龐大投資。製藥公司致力於開發創新治療方法以應對這種複雜的疾病，從而推動了競爭激烈的市場格局，其中活躍的臨床試驗和研究合作尤為突出。包括選擇性受體拮抗劑在內的新型治療方法的出現，預示著充滿活力的研發管線有望改善患者的治療效果。隨著各相關人員積極拓展產品組合，這種活性化的研發活動不僅有望帶來突破性治療方法，還將推動市場更廣泛地擴張，最終重塑多發性硬化症治療的未來。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Biogen Inc.（United States）
Teva Pharmaceutical Industries Ltd.（Israel）
Novartis AG（Switzerland）
Roche Holding AG（Switzerland）
Key Developments
Merck KGaA（Germany）
Bayer AG（Germany）
Johnson & Johnson（United States）
AbbVie Inc.（United States）
TG Therapeutics, Inc.（United States）
Acorda Therapeutics, Inc.（United States）
Alkermes plc（Ireland）
H. Lundbeck A/S（Denmark）
Eli Lilly and Company（United States）
GlaxoSmithKline plc（United Kingdom）
Pfizer Inc.（United States）
Celgene Corporation（United States）
Mallinckrodt Pharmaceuticals（United Kingdom）
UCB SA（Belgium）
Orion Corporation（Finland）

結論與建議

簡介目錄

Product Code: SQMIG35G2271

Global Multiple Sclerosis Market size was valued at USD 26.64 Billion in 2024 and is poised to grow from USD 27.25 Billion in 2025 to USD 32.69 Billion by 2033, growing at a CAGR of 2.3% during the forecast period (2026-2033).

The global multiple sclerosis (MS) landscape showcases a growing demand for innovative treatments, driven by the condition's immune-mediated nature that disrupts the central nervous system. Key characteristics, such as demyelination and neuroaxonal loss, highlight the urgent need for effective therapies. Monoclonal antibodies, including humanized variants, are at the forefront of treatment development, with numerous clinical trials aimed at discovering new drugs. The rising prevalence of MS emphasizes the significance of diagnosis and therapy, prompting government support for treatment initiatives. To fuel this market, major players are increasingly focusing on research and development, while collaborative efforts between pharmaceutical companies and academic institutions are further stimulating advancements in MS therapeutics, leading to a burgeoning drug industry focused on addressing diverse symptoms impacting patients.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multiple Sclerosis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Multiple Sclerosis Market Segments Analysis

Global Multiple Sclerosis Market is segmented by Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users and region. Based on Drug Class, the market is segmented into Immunomodulators, Immunosuppressants, Interferons and Others. Based on Diagnosis, the market is segmented into Magnetic Resonance Imaging (MRI), Simple Electrical Stimulation Tests, Lumbar Puncture and Others. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on End-Users, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Multiple Sclerosis Market

The growing prevalence of multiple sclerosis significantly fuels the expansion of the market. This neurological condition presents in various forms, including relapsing-remitting multiple sclerosis (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS), and progressive-relapsing MS (PRMS), each demonstrating a notable incidence that influences market dynamics. As the rates of these different types continue to rise, the demand for effective treatments and advanced therapies increases, driving innovation and investment within the sector. This heightened awareness and the search for better management options contribute to the overall growth trajectory of the global multiple sclerosis market.

Restraints in the Global Multiple Sclerosis Market

The growth of the global multiple sclerosis market may be hindered by several factors. The high costs associated with treating the disease can restrict accessibility and limit market expansion. Additionally, developing countries may struggle with insufficient healthcare infrastructure and a lack of qualified professionals, further complicating treatment availability. The repercussions of recent health crises have also led to a decline in clinical visits, which can impact patient engagement and care continuity. Moreover, widespread gaps in awareness surrounding multiple sclerosis contribute to challenges in patient education and diagnosis, ultimately acting as constraints on the overall growth potential of the market.

Market Trends of the Global Multiple Sclerosis Market

The Global Multiple Sclerosis market is witnessing a notable trend driven by substantial investments in research and development. Pharmaceutical companies are increasingly focused on advancing innovative treatment modalities to address this complex disease, fostering a competitive landscape characterized by robust clinical trials and collaborations with research institutions. The emergence of novel therapies, including selective receptor antagonists, is indicative of a thriving pipeline that promises to enhance patient outcomes. As various stakeholders actively engage in expanding their portfolios, this heightened R&D activity is poised to not only introduce groundbreaking therapies but also catalyze broader market expansion, ultimately reshaping the future of multiple sclerosis management.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Multiple Sclerosis Market Size by Drug Class & CAGR (2026-2033)

Market Overview
Immunomodulators
Immunosuppressants
Interferons
Others

Global Multiple Sclerosis Market Size by Diagnosis & CAGR (2026-2033)

Market Overview
Magnetic Resonance Imaging (MRI)
Simple Electrical Stimulation Tests
Lumbar Puncture
Others

Global Multiple Sclerosis Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Oral
Parenteral
Others

Global Multiple Sclerosis Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

Global Multiple Sclerosis Market Size by End-Users & CAGR (2026-2033)

Market Overview
Hospitals
Specialty Clinics
Homecare
Others

Global Multiple Sclerosis Market Size & CAGR (2026-2033)

North America (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
- US
- Canada
Europe (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Biogen Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TG Therapeutics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Acorda Therapeutics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alkermes plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
H. Lundbeck A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mallinckrodt Pharmaceuticals (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB S.A. (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Orion Corporation (Finland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments